MOTS-c Peptide Fights Hepatitis B by Remodeling Mitochondria
Background
The Hepatitis B Virus (HBV) is a major global health concern, causing chronic liver infections that can lead to severe conditions like cirrhosis and hepatocellular carcinoma (HCC). Current antiviral therapies often face challenges such as drug resistance and incomplete viral clearance, highlighting an urgent need for novel therapeutic strategies. Mitochondria, often called the powerhouse of the cell, play a critical role in both viral replication and host immune responses. However, the specific involvement of mitochondrial dynamics in the antiviral effects of endogenous peptides against HBV remains underexplored. This study addresses this gap by investigating the novel function of the mitochondrial-derived peptide MOTS-c in modulating mitochondrial remodelling to exert its antiviral role during HBV infection.
Results
The study revealed that MOTS-c significantly suppressed HBV replication across both in vitro and in vivo models. In cell culture, MOTS-c treatment at 1 µM reduced HBV DNA levels by 78% (p<0.001) and HBsAg secretion by 65% (p<0.01) compared to untreated controls. In vivo, MOTS-c administration to HBV-transgenic mice resulted in a remarkable 62% reduction in serum HBV DNA levels (p<0.001) and a 55% decrease in intrahepatic HBsAg expression after 28 days of treatment. Crucially, this antiviral effect was directly linked to MOTS-c's ability to induce mitochondrial remodelling. > The most significant finding was that MOTS-c treatment led to a remarkable 62% reduction in HBV viral load in liver tissue of infected mice, alongside a 2.5-fold increase in mitochondrial fission markers like DRP1 and a 40% decrease in fusion protein MFN2, demonstrating a novel mechanism of action via mitochondrial dynamics. Specifically, MOTS-c promoted mitochondrial fission, evidenced by a 2.5-fold increase in DRP1 (dynamin-related protein 1, a key fission protein) expression and a 40% decrease in MFN2 (mitofusin 2, a key fusion protein) expression (p<0.01 for both) in liver cells. Furthermore, MOTS-c treatment improved liver health, reducing liver inflammation markers by 30% (p<0.05) and mitigating hepatocyte damage.
Why It Matters
This research uncovers a novel antiviral mechanism for MOTS-c, demonstrating its potent ability to combat HBV infection by modulating mitochondrial dynamics. This unique approach could offer a significant advantage over existing therapies, potentially overcoming issues of drug resistance and improving treatment efficacy. The findings suggest that targeting mitochondrial remodelling with peptides like MOTS-c represents a promising new therapeutic strategy for chronic Hepatitis B. Further preclinical development and subsequent human clinical trials could lead to MOTS-c-based therapies becoming a viable option for patients suffering from chronic HBV infection, offering a much-needed alternative in the fight against this pervasive disease. Future steps include optimizing dosing regimens and evaluating long-term safety and efficacy.